BioSpace

Argenx shutters Sjogren's study, losing blockbuster expansion opportunity for Vyvgart

Argenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the company’s $2.2 billion Forte Biosciences buy.

By BioSpace

1 min read
Argenx shutters Sjogren's study, losing blockbuster expansion opportunity for Vyvgart
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights